526 related articles for article (PubMed ID: 2036661)
21. Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy.
Gottlieb DJ; Prentice HG; Heslop HE; Bello-Fernandez C; Bianchi AC; Galazka AR; Brenner MK
Blood; 1989 Nov; 74(7):2335-42. PubMed ID: 2804369
[TBL] [Abstract][Full Text] [Related]
22. Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo.
Schneekloth C; Körfer A; Hadam M; Lopez Hänninen E; Menzel T; Schomburg A; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
Acta Haematol; 1993; 89(1):13-21. PubMed ID: 7683166
[TBL] [Abstract][Full Text] [Related]
23. The efficacy of CD3 x CD19 bispecific monoclonal antibody (BsAb) in a clonogenic assay: the effect of repeated addition of BsAb and interleukin-2.
Haagen IA; Geerars AJ; de Lau WB; Bast BJ; de Gast BC
Blood; 1995 Jun; 85(11):3208-12. PubMed ID: 7538821
[TBL] [Abstract][Full Text] [Related]
24. Cellular cytotoxic function and potential in acute myelogenous leukaemia.
Lim SH; Worman CP; Jewell AP; Goldstone AH
Leuk Res; 1991; 15(7):641-4. PubMed ID: 1861545
[TBL] [Abstract][Full Text] [Related]
25. Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors.
Bosly A; Guillaume T; Brice P; Humblet Y; Staquet P; Doyen C; Chatelain B; Franks CR; Gisselbrecht C; Symann M
Exp Hematol; 1992 Sep; 20(8):962-8. PubMed ID: 1354620
[TBL] [Abstract][Full Text] [Related]
26. Proliferation and cytolytic function of anti-CD3 + interleukin-2 stimulated peripheral blood mononuclear cells following bone marrow transplantation.
Katsanis E; Anderson PM; Filipovich AH; Hasz DE; Rich ML; Loeffler CM; Ochoa AC; Weisdorf DJ
Blood; 1991 Sep; 78(5):1286-91. PubMed ID: 1831682
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients: II. Feasibility of LAK generation in children with active disease and in remission.
Adler A; Albo V; Blatt J; Whiteside TL; Herberman RB
Blood; 1989 Oct; 74(5):1690-7. PubMed ID: 2790193
[TBL] [Abstract][Full Text] [Related]
28. Correlation of blood lymphocyte CTLA-4 (CD152) induction in Hodgkin's disease with proliferative activity, interleukin 2 and interferon-gamma production.
Kosmaczewska A; Frydecka I; Boćko D; Ciszak L; Teodorowska R
Br J Haematol; 2002 Jul; 118(1):202-9. PubMed ID: 12100149
[TBL] [Abstract][Full Text] [Related]
29. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
[TBL] [Abstract][Full Text] [Related]
30. Cytotoxic protein expression in non-Hodgkin's lymphomas and Hodgkin's disease.
Kanavaros P; Vlychou M; Stefanaki K; Rontogianni D; Gaulard P; Pantelidaki E; Zois M; Darivianaki K; Georgoulias V; Boulland ML; Gorgoulis V; Kittas C
Anticancer Res; 1999; 19(2A):1209-16. PubMed ID: 10368677
[TBL] [Abstract][Full Text] [Related]
31. Distribution of lymphocytes with interleukin-2 receptors (TAC antigens) in reactive lymphoproliferative processes, Hodgkin's disease, and non-Hodgkin's lymphomas. An immunohistologic study of 300 cases.
Sheibani K; Winberg CD; van de Velde S; Blayney DW; Rappaport H
Am J Pathol; 1987 Apr; 127(1):27-37. PubMed ID: 3105322
[TBL] [Abstract][Full Text] [Related]
32. Expression and signal transduction of T-cell antigen receptor (TCR)/CD3 complexes on fresh or in vitro expanded T lymphocytes from patients with Hodgkin's and non-Hodgkin's lymphomas.
Rubin B; Martin EP; Arnaud J; Delsol G; Plesner T; Ratsimbazafy A; Llobera R; Holm B; Mariame B
Scand J Immunol; 1997 Jun; 45(6):715-25. PubMed ID: 9201313
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis C Virus and related changes in immunological parameters in non Hodgkin's lymphoma patients.
el-Din HM; Attia MA; Hamza MR; Khaled HM; Thoraya MA; Eisa SA
Egypt J Immunol; 2004; 11(1):55-64. PubMed ID: 15724387
[TBL] [Abstract][Full Text] [Related]
34. Bacterial infections in lymphoma patients treated with recombinant interleukin-2.
Lim SH; Giles FJ; Smith MP; Goldstone AH
Acta Haematol; 1991; 85(3):135-8. PubMed ID: 2042446
[TBL] [Abstract][Full Text] [Related]
35. A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects.
Vlasveld LT; Hekman A; Vyth-Dreese FA; Rankin EM; Scharenberg JG; Voordouw AC; Sein JJ; Dellemijn TA; Rodenhuis S; Melief CJ
Br J Cancer; 1993 Sep; 68(3):559-67. PubMed ID: 8353046
[TBL] [Abstract][Full Text] [Related]
36. CD30 distribution. Immunohistochemical study on formaldehyde-fixed, paraffin-embedded Hodgkin's and non-Hodgkin's lymphomas.
Miettinen M
Arch Pathol Lab Med; 1992 Nov; 116(11):1197-201. PubMed ID: 1332642
[TBL] [Abstract][Full Text] [Related]
37. Cytokine-mediated immunotherapy following autologous bone marrow transplantation in lymphoma and evidence of interleukin-2-induced immunomodulation in allogeneic transplants.
Slavin S; Nagler A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S59-67. PubMed ID: 9457396
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-2 therapy for refractory and relapsing lymphomas.
Tourani JM; Levy V; Briere J; Levy R; Franks C; Andrieu JM
Eur J Cancer; 1991; 27(12):1676-80. PubMed ID: 1782082
[TBL] [Abstract][Full Text] [Related]
39. Aminobisphosphonates prevent the inhibitory effects exerted by lymph node stromal cells on anti-tumor Vδ 2 T lymphocytes in non-Hodgkin lymphomas.
Musso A; Catellani S; Canevali P; Tavella S; Venè R; Boero S; Pierri I; Gobbi M; Kunkl A; Ravetti JL; Zocchi MR; Poggi A
Haematologica; 2014 Jan; 99(1):131-9. PubMed ID: 24162786
[TBL] [Abstract][Full Text] [Related]
40. Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.
Gratama JW; Bruin RJ; Lamers CH; Oosterom R; Braakman E; Stoter G; Bolhuis RL
Clin Exp Immunol; 1993 May; 92(2):185-93. PubMed ID: 8485906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
